Philippe Rochigneux

Medical Oncologist @paoli_calmettes (Marseille, France).

[Philippe Rochigneux @prochigneux]

@SabatierRenaud @paoli_calmettes @crcm_marseille @ProfAnthoG Thanks Renaud !!

[olimpio @OlimpioCrypto]

unleash it 🐙

https://t.co/0Z9jxlE7nT

[Maye Chat @MayeChatpu]

#GabrielAttal aurait donc décidé d’augmenter les places en 2eme année de médecine à 16000 en 2027. Très bonne idée. Mais il faut en même temps :
-augmenter les moyens des facs, des hôpitaux d’accueil et le nb d’enseignants
-conditionner dès le debut l’exercice ultérieur

[Philippe Rochigneux @prochigneux]

@jitcancer @MyeLau_Gorvel great news ! congrats Mathilde Beaufils and all the team @TumImmuno_CRCM !

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records https://t.co/zLLVUPM1fH @MyeLau_Gorvel @prochigneux

[Philippe Rochigneux @prochigneux]

@jitcancer @MyeLau_Gorvel great news ! congrats Mathilde Beaufils and all the team!

[Sherene Loi, MD @LoiSher]

Fantastic discussion of amazing plenary data @asco23 by fabulous @bensolomon1 #egfrmutant #NSCLC @PeterMacCC @PeterMacRes

[Myriam Chalabi @MyriamChalabi]

So great to see this out after #ESMO22! No doubt about it: neoadjuvant is here to stay! Congrats ⁦@DrSapnaPatel⁩ ⁦@EladSharonMD⁩ and team! Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma | NEJM https://t.co/7rg7Z8cy0C

[Philippe Rochigneux @prochigneux]

Delighted to have this PhD paper out in Clinical Cancer Reasearch! Immune predictors of Pembro efficacy in NSCLC. Great collab between Marseillle @paoli_calmettes @TumImmuno_CRCM and UCLA @dgsomucla. https://t.co/P61MMAi8ON

[Dipesh Uprety MD FACP @DipeshUpretyMD]

NEOpredict-Lung @myESMO: exploring the feasibility & efficacy of targeting PD-1 and LAG-3 prior to resection --> R0 resection rate was 97%. Complete or major histopathological response 30% in the combination arm @OncoAlert #ESMO2022

[Dipesh Uprety MD FACP @DipeshUpretyMD]

One of THE BEST PRESIDENTIAL Symposium @myESMO "What is the driver of a driver-mutant NSCLC"? by Dr. Swanton and an excellent discussion by Dr. Delaloge
-> PM 2.5 ↑es the risk of multiple tumors
-> PM 2.5 associated with ↑ed risk of EGFRm NSCLC #LCSM @OncoAlert #ESMO22

[d.planchard @dplanchard]

Always impressed by the rapidity of tumor regression after only 1 injection of Datopotamab deruxtecan (ADC-anti Trop2) (ICARUS-Lung01trial @GustaveRoussy ). NSCLC with an EGFRmut (Del19) after Osimertinib then Platinum-Pemetrexed-Pembrolizumab… @CICThoraciques

[Matteo Lambertini, MD PhD @matteolambe]

Out in @NEJM overall survival data from #KEYNOTE355 trial showing benefit of adding #pembrolizumab to chemotherapy as 1st-line treatment in advanced #PDL1+ triple-negative #BreastCancer: congrats super @JavierCortesMD @hoperugo et al!

@OncoAlert #bcsm

https://t.co/NQUGj4SXl0

[Tom Newsom-Davis @tnewsomdavis]

Lovely summary of where we are in EGFR Exon20 Insertion

#LCSM #ASCO22 @BTOGORG @EgfrUk

[Christophe Massard @drcmassard]

Kudos for RAGNAR trial preliminary results: one of the largest histology agnostic basket trial! FGFR is a target in hard to treat cancer such as gliome, pancreas or salivary gland cancer ⁦@y_loriot⁩ ⁦@GustaveRoussy⁩ ⁦@MDAndersonNews⁩

[Christophe Massard @drcmassard]

Targeting the undruggable after Kras: FIH TP53 Y220C mutation drug. Nice preliminary activity and huge effort to find a drug for patients ⁦@cathy_ileana_md⁩ ⁦@MDAndersonNews⁩

[NEJM @NEJM]

DESTINY-Breast04: In a phase 3 trial, trastuzumab deruxtecan resulted in longer progression-free and overall survival than the physician’s choice of chemo among patients with HER2-low breast cancer. #ASCO22 https://t.co/bgheQ1yolb

[Dr Riyaz Shah @DrRiyazShah]

NADIM II; stage IIIA-B; NAC chemo is chemoIO; high levels of multi station N2! carbo taxol backbone. Stunning results with pCR and MPR rates. pCR in high pdl1 > 60% #ASCO22 #LCSM @BTOGORG

[Andrea Cercek @AndreaCercek]

Very proud of our study published in @NEJM. 100% clinical complete response with dostarlimab alone in mismatch repair-deficient locally advanced #RectalCancer. No radiation or surgery! @ASCO #ASCO22 @MSKCancerCenter https://t.co/sZypoHBtj7

[FabriceAndre @FAndreMD]

Triple therapy with abiraterone + androgen deprivation + docetaxel is a new standard of care in de novo metastatic castration-sensitive prostate cancer (PEACE-1), by K Fizazi from ⁦@GustaveRoussy⁩ and coll published in ⁦@TheLancet⁩ https://t.co/ArUahmrMG2